Please use this identifier to cite or link to this item:
Title: Resources utilization and costs the yearbBefore and after starting treatment with Adalimumab in Crohn's Disease patients
Authors: Saro, C
Ceballos Santos, Daniel Sebastián 
Muñoz, F
De la Coba, C
Aguilar, MD
Lázaro, P
Iglesias Flores, E
Barreiro de Acosta, M
Hernández Durán, MD
Barrio, J
Bode Riestra, Antonio 
Salazar, LF
UNESCO Clasification: 32 Ciencias médicas
Keywords: Adalimumab
Crohn's disease
Resources utilization
Issue Date: 2015
Journal: Inflammatory Bowel Diseases 
Abstract: Background: This study examines the resources utilization in patients with Crohn's disease (CD) during the year before (Y - 1) and after (Y + 1) starting treatment with adalimumab and the drug's efficiency. Methods: Observational, multicenter, prospective cohort study of patients with CD naive to biological drugs. The proportion of patients with CD Activity Index (CDAI) <150 was considered as the effectiveness variable. Costs considered were direct costs (DC) related to the use of health care resources, and indirect costs (IC) related to sick leave in Y - 1 and Y + 1. Adalimumab efficiency was estimated as the incremental cost/effectiveness ratio. A deterministic sensitivity analysis was performed building 3 scenarios: base case, the least favorable, and the most favorable case for adalimumab. Results: In the cohort of 126 patients (50.8% men; age 39.1 ± 13.8 yr), the proportion of patients in remission increased from 34.1% by the end of Y - 1 to 83.3% by the end of Y + 1. Although the DC increase by the use of adalimumab, the use of doctor visits, emergency room visits, laboratory tests, diagnostic examinations, and nonbiological drug treatment were lower (P < 0.05) in Y + 1 than Y - 1. In the base case scenario, considering only DC, the incremental cost/effectiveness ratio was €31,308 and including IC, it was €28,936. In patients with CDAI > 150 at the onset, incremental cost/effectiveness ratio was €20,119 and €18,223, considering DC alone or included IC, respectively. Conclusions: In patients with CD, adalimumab increases pharmacological costs at the expense of biological therapy but reduces the cost of other drugs, the use of health care resources, and IC. Adalimumab efficiency is 30% greater in patients with CDAI > 150.
ISSN: 1078-0998
DOI: 10.1097/MIB.0000000000000413
Source: Inflammatory Bowel Diseases, [ISNN 1078-0998], v. 21 (7), p. 1631-1640, (July 2015)
Appears in Collections:Artículos
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.